Serum peptidome based biomarkers searching for monitoring minimal residual disease in adult acute lymphocytic leukemia

Table 4 Clinical features of patients in different ALL groups before chemotherapy

Clinical features	ALL
	Newly Diagnosed	CR	Refractory & Relapsed
Sex
Male	50	24	26
Female	34	20	19
Age (year)	31 (18-77)	29 (18-62)	27 (18-77)
WBC (×10⁹/L)	53 (0.9-367.4)	14.75 (3.01-39.65)	25.99 (0.45-102.56)
Hb (g/L)	70 (31-143)	108 (84-394)	75 (48-139)
PLT(×10⁹/L)	37(1-338)	105 (25-394)	45 (2-245)
Subtype	T 14	T 4	T 4
Subtype	B 70	B 40	B 41
Chromosome Abnormality	Ph + 20	Ph + 6	Ph + 10
	del (5) (p14) 2	21 + mar 1	del (5) (p14) 1
	21 + mar 2
Molecular Genetics Abnormality	bcr-abl 20	bcr-abl 6	bcr-abl 10
Sternal tenderness	54/84	20/44	27/45
Lymphadenectasis	50/84	25/44	26/45
Splenohepatomegalia	45/84	21/44	23/45
Curative effect	69/84	44/44	36/45

This table shows clinical features of ALL patients in different groups at the time of diagnosis. WBC: White blood cell; Hb: Hemoglobin; PLT: Platelet. Curative effect refers to achieving complete remission after 2 courses of standard chemotherapy.

ISSN: 1477-5956